INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) to hold its Annual General Meeting of Shareholders on June 28, 2012, in Marseilles, France

Transparency directive : regulatory news

11/06/2012 07:15

PRESS RELEASE

      INNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON
                       JUNE 28, 2012, IN MARSEILLES, FRANCE

Marseilles, France, June 11, 2012

Innate Pharma (Euronext Paris: FR0010331421 - IPH) will hold its Annual General
Meeting of Shareholders ("AGM") on June 28, 2012, at 9:30 am in its
headquarters, 117 avenue de Luminy, F-13009 Marseilles.

The Notice of Meeting of this AGM was published today in the French official
legal bulletin ("BALO"). The documentation regarding this AGM is made available
to shareholders in accordance with existing regulations and on the Company's
website.

Precision regarding the AGM:

Only shareholders having registered their shares at least three business days
prior to the date of the AGM, by midnight Paris time, will be able to attend.

Shareholders holding "au porteur" (bearer) shares will need to obtain an
"attestation de participation" (certificate of shareholding) from their
brokers. This "attestation de participation" must be attached to the proxy form
or to the appropriate voting form if shareholders wish to designate a proxy or
vote by mail. The "attestation de participation" may replace the admission card
for shareholders wishing to attend the AGM in person.

Written questions from shareholders must be received from the day of the
publication of the official Notice of Meeting of the AGM up until four business
days prior to the AGM:

* by registered letter, addressed to Innate Pharma, Shareholders Services,
  117 avenue de Luminy, BP 30191, F-13009 Marseilles, France or

* by e-mail to investors@innate-pharma.com.

Shareholders may obtain the legal documentation in preparation of the AGM (as
described in article R. 225-83 of the French "Code de Commerce") by sending a
request by regular mail or e-mail to the above mentioned addresses.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with
two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 80 employees as at March 31,
2012.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code      FR0010331421
Ticker code    IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                             Press enquiries

Laure-Hélène Mercier                      ATCG Press
Director, Investor Relations              Marielle Bricman
Phone: +33 (0)4 30 30 30 87               Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com               mb@atcg-partners.com

IPH_AGM 2012

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) to hold its Annual General Meeting of Shareholders on June 28, 2012, in Marseilles, France

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories